| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/21/2010 | US20100015172 Method to reduce the physiologic effects of drugs on mammals |
| 01/21/2010 | US20100015171 Vaccines comprising tb 10.4 |
| 01/21/2010 | US20100015170 Flagellin mutant vaccine |
| 01/21/2010 | US20100015169 Tumor Antigens |
| 01/21/2010 | US20100015168 Immunogenic compositions for streptococcus agalactiae |
| 01/21/2010 | US20100015167 in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells; vaccine comprising a protein that comprises human sucrase isomaltase protein |
| 01/21/2010 | US20100015166 Therapeutic antibodies |
| 01/21/2010 | US20100015164 Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a |
| 01/21/2010 | US20100015163 Dendritic cell potentiation |
| 01/21/2010 | US20100015162 treating interleukin-22 (IL-22)-associated disorder such as arthritis or psoriasis by administering the antibody in an amount sufficient to inhibit or reduce immune cell activity in the subject |
| 01/21/2010 | US20100015161 Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer |
| 01/21/2010 | US20100015160 Compositions and methods for diagnosing and treating endometriosis |
| 01/21/2010 | US20100015159 Compositions and methods for treating kidney disease |
| 01/21/2010 | US20100015158 Method for treating atrophic age related macular degeneration |
| 01/21/2010 | US20100015157 Antibody formulations |
| 01/21/2010 | US20100015156 Diagnosis of inflammatory bowel disease in children |
| 01/21/2010 | US20100015155 Pegylated abeta fab |
| 01/21/2010 | US20100015154 Immunogenic memapsin 2 b-secretase peptides and methods of use |
| 01/21/2010 | US20100015153 Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same |
| 01/21/2010 | US20100015152 Diagnostic and therapeutic methods |
| 01/21/2010 | US20100015151 Polypeptides from neisseria meningitidis |
| 01/21/2010 | US20100015150 Tdf-related compounds and analogs thereof |
| 01/21/2010 | US20100015149 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/21/2010 | US20100015148 Methods and compositions for the utilization and targeting of osteomimicry |
| 01/21/2010 | US20100015147 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside |
| 01/21/2010 | US20100015146 Treating diabetes using inhibitors of il-1 |
| 01/21/2010 | US20100015145 Use of a compound for reducing the biological effectiveness of IL-6 |
| 01/21/2010 | US20100015144 Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| 01/21/2010 | US20100015143 Compositions and Methods Relating to Modulation of Immune System Components |
| 01/21/2010 | US20100015142 Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity |
| 01/21/2010 | US20100015141 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 01/21/2010 | US20100015140 Inhibitor Compounds and Cancer Treatment Methods |
| 01/21/2010 | US20100015139 METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| 01/21/2010 | US20100015138 Crystal structure of Staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
| 01/21/2010 | US20100015137 Receptor that binds trail |
| 01/21/2010 | US20100015136 Camptothecin-peptide conjugates and pharmaceutical compositions containing the same |
| 01/21/2010 | US20100015135 Anti-ephb4 antibodies and methods using same |
| 01/21/2010 | US20100015134 Therapy With CD4 Binding Peptides and Radiation |
| 01/21/2010 | US20100015133 Methods for Producing Polypeptides by Regulating Polypeptide Association |
| 01/21/2010 | US20100015132 Uses of mammalian cytokines and agonists; related reagents |
| 01/21/2010 | US20100015131 Composition Comprising Antibodies to LINGO or Fragments Thereof |
| 01/21/2010 | US20100015130 Disc-1 pathway activators in the control of neurogenesis |
| 01/21/2010 | US20100015129 Methods of using F-spondin as a biomarker for cartilage degenerative conditions and bone diseases |
| 01/21/2010 | US20100015128 GRP78 as a Predictor of Responsiveness to Therapeutic Agents |
| 01/21/2010 | US20100015127 Treatment for demyelinating disease |
| 01/21/2010 | US20100015126 Methods of Binding of Cross-Beta Structures By Chaperones |
| 01/21/2010 | US20100015125 Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion |
| 01/21/2010 | US20100015124 Modulation of epidermal growth factor heterodimer activity |
| 01/21/2010 | US20100015108 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 01/21/2010 | US20100015096 Fusion Proteins of Mycobacterium Tuberculosis |
| 01/21/2010 | US20100015087 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 01/21/2010 | US20100015048 Internalizing Anti-CD74 Antibodies and Methods of Use |
| 01/21/2010 | US20100015047 Lung-Expressed Polypeptides |
| 01/21/2010 | US20100015046 Camptothecin-Binding Moiety Conjugates |
| 01/21/2010 | US20100015045 Cancerous Disease Modifying Antibodies |
| 01/21/2010 | DE102008033175A1 Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung Silica nanoparticles and their use for vaccination |
| 01/21/2010 | DE10004815B4 Menschliche intestinale Natriumphosphat-Kotransporter Human intestinal sodium phosphate cotransporter |
| 01/21/2010 | CA2736311A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | CA2734714A1 Vaccines comprising tb10.4 |
| 01/21/2010 | CA2731216A1 Compositions for the detection and treatment of colorectal cancer |
| 01/21/2010 | CA2731194A1 Chimeric respiratory syncytial virus polypeptide antigens |
| 01/21/2010 | CA2731129A1 Cancerous disease modifying antibodies |
| 01/21/2010 | CA2730890A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 01/21/2010 | CA2730773A1 Methods and products for treating proliferative diseases |
| 01/21/2010 | CA2730742A1 Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| 01/21/2010 | CA2730737A1 Immunogenic amphipathic peptide compositions |
| 01/21/2010 | CA2730686A1 Anti-amyloid immunogenic compositions, methods and uses |
| 01/21/2010 | CA2730668A1 New influenza virus immunizing epitope |
| 01/21/2010 | CA2730620A1 Human cytomegalovirus neutralising antibodies and use thereof |
| 01/21/2010 | CA2730063A1 Compositions and methods of use for therapeutic antibodies |
| 01/21/2010 | CA2730050A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| 01/21/2010 | CA2727278A1 Novel synergistic effects |
| 01/21/2010 | CA2703519A1 Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| 01/20/2010 | EP2145961A2 Porcine adenovirus type 3 genome |
| 01/20/2010 | EP2145954A1 Anti-A33 antibody |
| 01/20/2010 | EP2145898A1 Anti-amyloid immunogenic compositions, methods and uses |
| 01/20/2010 | EP2145897A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/20/2010 | EP2145192A1 Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
| 01/20/2010 | EP2145003A2 Polynucleotides and polypeptides involved in gestational malaria, and biological applications |
| 01/20/2010 | EP2144998A1 Methods and compositions for live attenuated viruses |
| 01/20/2010 | EP2144997A1 Cancerous disease modifying antibodies |
| 01/20/2010 | EP2144934A1 Antibodies against il-25 |
| 01/20/2010 | EP2144933A2 Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases |
| 01/20/2010 | EP2144932A1 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| 01/20/2010 | EP2144931A2 Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| 01/20/2010 | EP2144930A1 Single chain fc, methods of making and methods of treatment |
| 01/20/2010 | EP2144928A2 Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor |
| 01/20/2010 | EP2144924A1 Fusion protein vaccine |
| 01/20/2010 | EP2144629A1 Method for stabilizing a protein |
| 01/20/2010 | EP2144628A2 Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| 01/20/2010 | EP2144617A1 Delivery of flu antibodies to surfaces in contact with air |
| 01/20/2010 | EP2144615A2 Methods of use of gamma inhibitor compounds for the attenuation of pain |
| 01/20/2010 | EP2144613A2 Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| 01/20/2010 | EP2144606A2 Remedy for the treatment of cardio-vascular diseases or disorders |
| 01/20/2010 | EP2012822B1 Modified adenovirus hexon protein and uses thereof |
| 01/20/2010 | EP1861418B1 T cd4+ epitopes of type i and ii latency antigens of the epstein-barr virus, which can be recognised by the majority of individuals in the caucasian population and applications thereof |
| 01/20/2010 | EP1774332B1 Immune response assessment method |
| 01/20/2010 | EP1599227B1 Methods of immunomodulation in animals |
| 01/20/2010 | EP1571211B1 Antibodies against lesional tissues |
| 01/20/2010 | EP1554383B1 Recombinant mva strains as potential vaccines against p. falciparum malaria |